Alvotech
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lisa Graver
- Full Time Employees
- 1,279
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9, Rue de Bitbourg Luxembourg LU Luxembourg 1273
- IPO Date
- Jun 16, 2022
- CIK
- 0001898416
- Website
- alvotech.com
- Similar Companies
- Business
- Alvotech Ltd (ALVO) is an Iceland-based biotechnology company that develops, manufactures and commercializes biosimilar and novel biologic drugs targeting autoimmune, eye and other diseases. The company offers a portfolio of products including AVT02, a biosimilar to Humira (adalimumab) for treating rheumatoid arthritis, psoriasis and other inflammatory conditions; AVT04, a biosimilar to Stelara (ustekinumab) for psoriasis and Crohn's disease; AVT06, a biosimilar to Eylea (aflibercept) for retinal diseases; and AVT23, a biosimilar candidate to Keytruda (pembrolizumab) for oncology indications, along with pipeline candidates in ophthalmology and other therapeutic areas. Alvotech operates primarily in the United States, Europe and select emerging markets through strategic partnerships with companies such as Teva Pharmaceutical Industries, STADA Arzneimittel, Biocon Biologics and Intas Pharmaceuticals for commercialization and distribution. Founded in 2013 and headquartered in Reykjavik, Iceland, the company focuses on high-quality biosimilars produced using its proprietary continuous manufacturing platform to improve yield, reduce costs and accelerate market entry. In recent developments, Alvotech secured U.S. FDA approval for AVT04 (Selarsdi) in October 2024 and launched it commercially through its partner Teva in early 2025; expanded its partnership with Biocon for AVT02 commercialization in Europe; completed a significant funding round in 2024 to support pipeline advancement; and announced positive Phase 3 topline results for AVT06 in mid-2025, positioning it for regulatory submission.
Company News
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
Alvotech to present at upcoming investor conferences in September
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
Alvotech Q2 Earnings Call Highlights
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
Alvotech to Report Financial Results for H1 2026
Alvotech announces successful closure of FDA inspection of manufacturing facility
Transactions of Managers and Closely Associated Persons
Alvotech further strengthens liquidity by securing term loan facility of $75 million
Transactions of Managers and Closely Associated Persons
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Transactions of Managers and Closely Associated Persons